A patient with a pharyngeal-cervicalbrachial variant of GuilIlain-Barre' syndrome had anti-GTla and anti-GDla antibodies (IgG) in the serum. The activities of anti-GTla antibodies were stronger than anti-GDla antibodies and their activities declined later in the clinical course. These two different antibodies bound independently to each ganglioside in an absorption study with polystyrene beads coated with GTla or GDla. motor nerve conduction velocity studies showed that compound action potentials of the ulnar and peroneal nerves were normalised by the 24th day. He was discharged 60 days after admission with almost full recovery except for the facial and neck muscles. The strength of his neck muscles had fully recovered by three months and his facial muscles by six months after discharge.
Accepted 8 March 1994 Antiganglioside antibodies have Antigenic gangliosides, which included GM3, GM2, GM1a, GD1a, GD1b, GTlb, and GQlb, were prepared from bovine brains by Q sepharose column chromatography according to the method of Hirabayashi et al.' GTla was a gift from Dr S Ando (Tokyo Metropolitan Institute of Gerontology). The ELISA was carried out by the method of Higashi et al. 4 The antigenic solution contained 20 pmol of each ganglioside. After blocking with 5% bovine serum albuminphosphate buffered saline (BSA-PBS), triplicate samples of serum were diluted 1:100 with 0-25% BSA-PBS and incubated for two hours at room temperature. An absorption study was performed with GTla or GDla coated polystyrene beads as follows: a total of 2-5 mg of polystyrene beads (MW 50 000, Polysciences Inc) was added to 1 ml of chloroform-methanol solution (2:1 v/v), containing 1 mg of GT1 a or GD1 a. The solution was dried by rotary evaporator and the beads were suspended in 5 ml PBS. The patient's serum, diluted at 1:50 with 0-25% BSA-PBS, was mixed with the same volume of PBS containing GTla or GDla coated polystyrene beads. The solution was incubated at 37°C for 30 minutes, centrifuged at 3000 rpm for 15 minutes, and the supernatant was used as the primary antibody for ELISA. As a control, PBS was used instead of GDla coated polystyrene beads.
Results
We detected anti-GTIa and anti-GDla IgG antibodies in this patient's serum. Antibody activities against the other gangliosides used in this study could not be detected. AntiGTla antibodies reacted more strongly than anti-GDla antibodies (figure). Both antiGTla and -GDla antibodies showed their highest activities on the 2nd day after admission, declined with clinical course, and could not be detected after six months (figure).
In the absorption study, when the patient's serum was preincubated with GTl a coated polystyrene beads, anti-GTIa antibody was absorbed on to the beads, but anti-GD1a antibody activities did not decrease. On the other hand, the activities of anti-GTla antibody did not decrease when the patient's serum was preincubated with GD 1 a coated polystyrene beads or only with PBS.
We also detected anti-GM1a IgG antibodies in two of seven typical patients with Guillain-Barre syndrome, anti-GQlb and anti-GTl a IgG antibodies in all eight patients with Miller-Fisher syndrome tested, and IgM antibodies against polysialogangliosides in a patient with macroglobulinaemia and sensory dominant neuropathy.7 No IgG or IgM antibody activities against the eight gangliosides used in this study were detected in the serum of the other patients-namely, those with amyotrophic lateral sclerosis (n = 33), multiple sclerosis (n = 3), myasthenia gravis (n = 12), and other neurological diseases (n = 154), or normal controls at a dilution of 1:100.
Discussion
In 1986, Ropper reported three patients who, like ours, developed prominent weakness of the pharyngeal-cervical-brachial regions without either lower limb weakness or sensory disturbance, and labelled it "pharyngealcervical-brachial weakness resembling botulism or diphtheria".5 Conduction block in the ulnar and peroneal nerves in our patient was compatible with postinfectious demyelinating polyneuropathy.
From our results it is suggested that the detected antibodies, anti-GTla and antiGDla, participated in the pathological process of this patient, and that these two different antibodies independently reacted with GTla and GD1a. Ilyas et al detected two kinds of anti-ganglioside antibodies in two patients with Guillain-Barre syndrome.' Their antibodies, however, reacted with the common structure of GD1a and GT1b, GalNAc-Gal-NeuAc-NeuAc. To our knowledge, there is no other report of a patient who has two antibodies reacting independently with a different ganglioside without sharing a common structure.
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